Gyre Therapeutics, INC Schedule 13D activist filings

Gyre Therapeutics, Inc. has finalized its acquisition of Cullgen Inc. in an all-stock transaction valued at approximately $300 million, with a shareholder meeting scheduled for June 10, 2026, to approve the conversion of Series B Preferred Stock.

Gyre Therapeutics has finalized its all-stock merger with Cullgen Inc., resulting in significant ownership changes and the issuance of new convertible preferred stock.

Gyre Therapeutics has finalized its $300 million all-stock acquisition of Cullgen Inc., significantly expanding its corporate footprint.